共 97 条
[11]
Carter RA(2012)Voriconazole in clinical practice J Chemother 24 311-327
[12]
Crippa F(2002)Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408-415
[13]
Wald A(2010)Isavuconazole: a comprehensive review of spectrum of activity of a new triazole Mycopathologia 170 291-313
[14]
Corey L(2016)Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial J Med Econ 19 728-734
[15]
Upton A(2006)The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology J Am Acad Dermatol 55 490-500
[16]
Kirby KA(2011)Direct economic burden of chronic hepatitis C virus in a United States managed care population J Clin Gastroenterol 45 e17-e24
[17]
Carpenter P(2008)Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients Arch Dermatol 144 35-39
[18]
Boeckh M(2012)Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 335-343
[19]
Marr KA(2013)Cost utility of early versus delayed laparoscopic cholecystectomy for acute cholecystitis Surg Endosc 27 256-262
[20]
Kim A(2013)The economic burden of visual impairment and blindness: a systematic review BMJ Open 3 e003471-1511